依碳酸舍格列净 | 408504-26-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 依碳酸舍格列净
• 中文别名: 2-[(4-甲氧基苯基)甲基]苯基-beta-D-吡喃葡萄糖苷-6-(乙基碳酸酯)；2-[(4-甲氧基苯基)甲基]苯基-BETA-D-吡喃葡萄糖苷-6-(乙基碳酸酯)
• 英文名称: Sergliflozin etabonate
• 英文别名: 2-{[4-(ethyloxy)phenyl]methyl}phenyl-6-O-[(ethyloxy)carbonyl]-β-D-glucopyranoside；6-O-ethoxycarbonyl-2-[(4-methoxyphenyl)methyl]phenyl-β-D-glucopyranoside；sergliflozin；2-(4-methoxybenzyl)phenyl 6-O-ethoxycarbonyl-β-D-glucopyranoside；ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(4-methoxyphenyl)methyl]phenoxy]oxan-2-yl]methyl carbonate
• CAS: 408504-26-7
• 化学式: C₂₃H₂₈O₉
• 分子量: 448.47
• InChiKey: QLXKHBNJTPICNF-QMCAAQAGSA-N

物化性质

• 沸点：
  611.5±55.0 °C(Predicted)
• 密度：
  1.312

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  124
• 氢给体数：
  3
• 氢受体数：
  9

制备方法与用途

依他波酸司格列净（GW-869682X）是一种有效的口服活性SGLT2抑制剂，具有抗糖尿病和降血糖作用。研究表明，这种药物能显著降低糖尿病小鼠的非空腹血糖水平，并且有潜力用于进一步研究糖尿病[1]。

反应信息

• 作为产物：
  描述：

  2-[(4-甲氧基苯基)甲基]苯酚 在 吡啶 、 2,6-二甲基吡啶 、 三氟化硼乙醚 、 sodium methylate 、 三乙胺 作用下， 以 甲醇 、 丙酮 、 甲苯 为溶剂， 反应 9.0h， 生成 依碳酸舍格列净
  参考文献：
  名称：

  An Efficient and Practical Preparation of a Potent Low-Affinity Na+-Dependent Glucose Cotransporter (SGLT2) Inhibitor, Sergliflozin Etabonate

  摘要：

  The development of an efficient and practical process for the preparation of Sergliflozin etabonate (1), a prodrug of a novel selective low-affinity Na+-dependent glucose cotransporter (SGLT2) inhibitor, Sergliflozin (2), is described. Its development required a suitable process for large-scale manufacturing. We established a chromatography-free approach for 2-[(4-methoxyphenyl)methyl]phenol (5), the efficient O-glycosylation of 5 with penta-O-acetyl-beta-D-glucopyranose (7) without using a trichloroacetimidate intermediate (9), and efficient reaction conditions to introduce an ethoxycarbonyl group onto the primary alcohol of 2 with high selectivity. This process provided 1 with a 45% overall yield from anisole (10).

  DOI：

  10.3987/com-16-13484

文献信息

• Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof
  申请人：JAEHNE Gerhard

  公开号：US20110178134A1

  公开（公告）日：2011-07-21

  The invention relates to compounds of formula (I) wherein the groups have stated meanings, and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

  本发明涉及具有所述意义的公式（I）的化合物，以及它们的生理相容性盐。所述化合物适用于例如作为抗肥胖药物和治疗心血管代谢综合征。
• AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES
  申请人：Petry Stefan

  公开号：US20130157941A1

  公开（公告）日：2013-06-20

  The present invention relates to azolopyridin-3-one derivatives of the general formula (I) with the meanings specified in the description, to their pharmaceutically usable salts and to their use as drug substances.

  本发明涉及通式（I）所示的咪唑吡啶-3-酮衍生物，其含义如描述中所指定的，以及它们的药用盐和作为药物物质的用途。
• [EN] MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR GPR119 ET TRAITEMENT DE TROUBLES QUI LUI SONT ASSOCIÉS
  申请人：ARENA PHARM INC

  公开号：WO2012135570A1

  公开（公告）日：2012-10-04

  The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single agent or in combination with one or more pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, or an alpha-glucosidase inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

  本发明涉及式(Ia)化合物以及药用可接受的盐、溶剂化物和水合物，它们作为单一药剂或与一个或多个药物制剂如DPP-IV抑制剂、双胍类药物或α-葡萄糖苷酶抑制剂联合使用，在例如治疗以下疾病中有用：GPR119受体相关疾病；通过增加血液中肠促胰岛素水平而改善的状况；代谢相关疾病；2型糖尿病；肥胖；及其相关并发症。
• Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof
  申请人：JAEHNE Gerhard

  公开号：US20110053947A1

  公开（公告）日：2011-03-03

  The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.

  本发明涉及具有公式（I）的化合物，其中R和R'、A、D、E、G、L、p以及R1至R10具有所述含义，以及它们的生理相容性盐。所述化合物例如可作为抗肥胖药物使用。
• Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
  申请人：JAEHNE Gerhard

  公开号：US20090215728A1

  公开（公告）日：2009-08-27

  This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R′, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

  这项发明涉及公式（I）中的芳基氨基芳基烷基取代的咪唑烷二酮及其生理耐受的盐： 其中R、R'、R1至R10、A、D、E、G、L和p如本文所定义。该发明还涉及制备它们的方法、包含它们的药物组合物以及它们的治疗用途。这些化合物适用于例如作为抗肥胖药物和治疗心脏代谢综合征。